Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Vor Bio (Nasdaq: VOR), a clinical-stage biotech company, announced inducement grants to seven new employees between August 4-18, 2025. The grants include 6,959,013 stock options and 1,491,217 restricted stock units (RSUs).

The stock options have exercise prices of $2.04-$2.11 per share with a ten-year term. Both options and RSUs follow a four-year vesting schedule, with 25% vesting after 12 months, followed by monthly vesting for options and quarterly vesting for RSUs over the next 36 months. These grants were made under the Vor Biopharma Inc. 2023 Inducement Plan in compliance with Nasdaq Listing Rule 5635(c)(4).

Positive

• Significant equity incentives to attract new talent
• Structured vesting schedule promotes employee retention

Negative

• Potential dilution for existing shareholders from nearly 8.5 million new shares

CAMBRIDGE, Mass., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, between August 4, 2025, and August 18, 2025, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 6,959,013 shares of Vor Bio’s common stock and restricted stock units (“RSUs”) representing the right to receive an aggregate of 1,491,217 shares of Vor Bio’s common stock to seven newly hired employees. The foregoing stock options and RSUs were granted as material inducements to employment with Vor Bio in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the Vor Biopharma Inc. 2023 Inducement Plan (the “Inducement Plan”).        

The stock options have a ten-year term and exercise prices ranging from $2.11 to $2.04 per share, which is equal to the closing price of Vor Bio’s common stock on the respective grant dates of the stock options and RSUs. The options will vest over a four-year period, with 25% of the shares vesting after 12 months and the remaining shares vesting monthly over the following 36 months, subject to the employees’ continued employment with Vor Bio on such vesting dates. The RSUs will vest over a four-year period, with 25% of the shares vesting after 12 months and the remaining shares vesting quarterly over the following 36 months, subject to the employees’ continued employment with Vor Bio on such vesting dates. The options and RSUs are subject to the terms and conditions of the Inducement Plan and the terms and conditions of an award agreement covering the grants.

About Vor Bio

Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and commercialization to address serious autoantibody-driven conditions worldwide. For more information visit www.vorbio.com

Media & Investor Contacts:
Carl Mauch
cmauch@vorbio.com

Sarah Spencer
investors@vorbio.com

FAQ

How many shares were granted in Vor Bio's (VOR) August 2025 inducement grants?

Vor Bio granted options for 6,959,013 shares and RSUs for 1,491,217 shares, totaling approximately 8.45 million shares.

What is the vesting schedule for Vor Bio's (VOR) August 2025 inducement grants?

Both options and RSUs vest over 4 years, with 25% vesting after 12 months. The remaining options vest monthly and RSUs vest quarterly over the following 36 months.

What is the exercise price for Vor Bio's (VOR) August 2025 stock options?

The stock options have exercise prices ranging from $2.04 to $2.11 per share, equal to VOR's closing price on the respective grant dates.

How many employees received Vor Bio's (VOR) August 2025 inducement grants?

Seven newly hired employees received the inducement grants from Vor Bio.